Journal of Health Sciences & Surveillance System

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Seroprevalence of COVID-19 Antibodies and Factors Associated with Seropositivity: A Population-based Study

Document Type : Original Article

Authors

1 Department of Public Health, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran

2 Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran

3 Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran

4 Molecular and Medicine Research Center, Khomein University of Medical Sciences, Khomein, Iran

Abstract

Background: Currently, COVID-19 is a global public health problem. This study aimed to estimate the seroprevalence of antibodies related to Covid-19 in the general population in southern Iran.
Methods: This cross-sectional population-based study of the seroepidemiological type investigated the serological prevalence of COVID-19 from October to December 2020 in Jahrom, Fars province, Iran. A total of 612 participants were selected using multistage cluster random sampling regardless of age or gender. The dataset in the study included the participants’ demographic information, the history of exposure to COVID-19 patients, the history of PCR tests, and the history of COVID-19 symptoms in previous months. In addition, this study examined the raw and survey weight adjusted estimates with Stata version 14. Finally, logistic regression was performed to identify risk factors for serum prevalence.
Results: The participants’ mean age was 38.88±13.91 and the majority were 30 to 49 years (51.4%), with a female preponderance (58.7%). The estimated adjusted seroprevalence was 32.66 (95%CI: 28.93-36.63), with 207 positive cases for either IgG or IgM. The results of multivariable logistic regression showed that seropositivity in the participants was 4.95 times more likely associated with a history of positive PCR test (OR: 4.95, 95%CI: 2.46-10.90) and 2.14 times in patients with a history of muscle pain in previous months (OR: 2.14, 95%CI: 1.03-4.47).
Conclusion: The actual number of patients with COVID-19 is significantly higher than the number of cases confirmed by the disease monitoring system based on PCR tests. Therefore, tracking individuals’ contact with confirmed patients using extensive testing and segregation of asymptomatic patients can help control the epidemic.

Keywords

References
  1. Jahanbin K, Rahmanian V. Using Twitter and web news mining to predict COVID-19 outbreak. Asian Pac J Trop Med. 2020;13(8):378. doi: 10.4103/1995-7645.279651.
  2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. PMID: 31978945; PMCID: PMC7092803.
  3. COVID-19 CORONAVIRUS PANDEMIC 2021 [June 21 2021]. Available from:https://www.worldometers.info/coronavirus/‎.
  4. Esmaeilzadeh N, Shakeri S, Esmaeilzadeh M, Rahmanian V. ARIMA models to forecasting the SARS-COV-2 in the Islamic Republic of Iran. Asian Pac J Trop Med. 2020;13(2):1-4. doi: 10.4103/1995-7645.291407.
  5. Total Coronavirus Cases in Iran 2021 [June 18 2021]. Available from:https://www.worldometers.info/coronavirus/country/iran/‎.
  6. Laboratory diagnostics for novel coronavirus 2020. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-‎guidance/laboratory.
  7. Zahedi R, Khorshidsavar H, Rahmanian V, Sharifi N. Accuracy of RT-PCR Test in diagnosing COVID-19: A retrospective Study. Pakistan J Med Health Sci. 2021;15(2):534-8.
  8. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-m, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154-155. doi: 10.1016/j.ijid.2020.03.020. PMID: 32179137; PMCID: PMC7270890.
  9. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180. Erratum in: Euro Surveill. 2020;25(22): PMID: 32183930; PMCID: PMC7078829.
  10. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. PMID: 31986261; PMCID: PMC7159286.
  11. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410-411. doi: 10.1016/S1473-3099(20)30114-6. PMID: 32087116; PMCID: PMC7158985.
  12. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-1179. doi: 10.1056/NEJMc2001737. PMID: 32074444; PMCID: PMC7121626.
  13. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377-381. doi: 10.15585/mmwr.mm6913e1. PMID: 32240128; PMCID: PMC7119514.
  14. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663-1665. doi: 10.1056/NEJMc2005073. PMID: 32187458; PMCID: PMC7121177.
  15. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12-16. doi: 10.1016/j.jmii.2020.05.001. PMID: 32425996; PMCID: PMC7227597.
  16. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol. 2020 May 26;58(6):e00512-20. doi: 10.1128/JCM.00512-20. PMID: 32245835; PMCID: PMC7269383.
  17. Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R; et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill. 2020;25(12):2000256. doi: 10.2807/1560-7917.ES.2020.25.12.2000256. PMID: 32234121; PMCID: PMC7118348.
  18. Rahmanian V, Rabiee MH, Sharifi H. Case fatality rate of coronavirus disease 2019 (COVID-19) in Iran-a term of caution. Asian Pac J Trop Med. 2020;13(7):328. doi: 10.4103/1995-7645.281617.
  19. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. Clin Infect Dis. 2021;72(2):249-253. doi: 10.1093/cid/ciaa849. PMID: 33501969; PMCID: PMC7337681.
  20. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(3):331-340. doi: 10.1016/j.cmi.2020.10.020. PMID: 33228974; PMCID: PMC7584920.
  21. Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis. 2021;27(2):636-638. doi: 10.3201/eid2702.201960. PMID: 33349310; PMCID: PMC7853569.
  22. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, March 17 2020. World Health Organization; 2020.
  23. Mousavi SA, Rouhanizadeh H, Saeedi M, Moosazadeh M, Ajami A, Fendereski A, et al. Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran. Asian Pac J Trop Med. 2021;14(1):10. doi: 10.4103/1995-7645.304296.
  24. Tabanejad Z, Darvish S, Boroujeni ZB, Asadi SS, Mesri M, Raiesi O, et al. Seroepidemiological Study of Novel Corona Virus (CoVID-19) in Tehran, Iran. medRxiv. 2021. doi: 10.1101/2021.01.18.20248911.
  25. Mirjalili MR, Namayandeh SM, Lotfi MH, Dehghani MR, Mirzaei M, Talebi AR, et al. COVID-19 Seroepidemiology Study of Yazd Province, First Peak, Spring 2020: A Population-Based Cross-Sectional Study. Journal of Shahid Sadoughi University of Medical Sciences. 2020;28(12):3338-50.
  26. Song SK, Lee DH, Nam JH, Kim KT, Do JS, Kang DW, et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea. J Korean Med Sci. 2020;35(29):e269. doi: 10.3346/jkms.2020.35.e269. PMID: 32715672; PMCID: PMC7384903.
  27. McCulloch DJ, Jackson ML, Hughes JP, Lester S, Mills L, Freeman B, et al. Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020. PLoS One. 2021;16(5):e0252235. doi: 10.1371/journal.pone.0252235. PMID: 34043706; PMCID: PMC8158900.
  28. Inbaraj LR, George CE, Chandrasingh S. Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. PLoS One. 2021;16(3):e0249247. doi: 10.1371/journal.pone.0249247. PMID: 33788873; PMCID: PMC8011723.
  29. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. PMID: 32645347; PMCID: PMC7336131.
  30. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 Aug 1;396(10247):313-319. doi: 10.1016/S0140-6736(20)31304-0. PMID: 32534626; PMCID: PMC7289564.
  31. Hensel J, McAndrews KM, McGrail DJ, Dowlatshahi DP, LeBleu VS, Kalluri R. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci Rep. 2020;10(1):18377. doi: 10.1038/s41598-020-75491-x. PMID: 33110184; PMCID: PMC7591473.
  32. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. Int J Epidemiol. 2021;50(2):410-419. doi: 10.1093/ije/dyab010. PMID: 33615345; PMCID: PMC7928865.
  33. Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. Emerg Infect Dis. 2020;26(6):1339-1441. doi: 10.3201/eid2606.200320. PMID: 32168463; PMCID: PMC7258483.
  34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Erratum in: Lancet. 2020 Jan 30. PMID: 31986264; PMCID: PMC7159299.
  35. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. J Assoc Med Microbiol Infect Dis Can. 2020;5(4):223-234. doi: 10.3138/jammi-2020-0030. PMID: 36340059; PMCID: PMC9602871.
  36. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11(1):53. doi: 10.1186/s13293-020-00330-7. PMID: 32948238; PMCID: PMC7498997.
  37. Li Y, Jerkic M, Slutsky AS, Zhang H. Molecular mechanisms of sex bias differences in COVID-19 mortality. Crit Care. 2020;24(1):405. doi: 10.1186/s13054-020-03118-8. PMID: 32646459; PMCID: PMC7347256.
Journal of Health Sciences & Surveillance System
Volume 11, 1 (Supplement)
January 2023
Pages 202-209
Files
Share
How to cite
Statistics